Company: ARWR
Filing Date: 2025-01-29
Form Type: ARS
Source: 0001628280-25-002866
Chunk: 174

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: ARS
Chunk 174
---
 will have no effect on the outcome of the vote. Because Proposal Three has three possible substantive responses (every one, two or three years), if none of the frequency alternatives receives the Required Vote, then we will consider stockholders to have approved the frequency that receives the greatest number of the votes cast. THE BOARD UNANIMOUSLY RECOMMENDS THAT STOCKHOLDERS SELECT “1 YEAR” ON THE PROPOSAL CONCERNING THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE Table of Contents 2025 PROXY STATEMENT Proposal Two — Advisory Vote to Approve Executive Compensation 21

Executive Compensation COMPENSATION DISCUSSION AND ANALYSIS The following compensation discussion and analysis contains statements regarding future individual and Company performance targets and goals. These targets and goals are disclosed in the limited context of Arrowhead’s executive compensation program and should not be understood to be statements of management’s expectations or guidance. Arrowhead cautions investors not to apply these statements to other contexts. Fiscal years are denoted as fiscal years, all other year references refer to calendar years. This Compensation Discussion and Analysis describes the compensation program for our NEOs. During fiscal 2024, these individuals were: • Christopher Anzalone, our President and Chief Executive Officer (our “CEO”); • James Hamilton, our Chief of Discovery and Translational Medicine (our “CDTM”); • Kenneth Myszkowski, our Chief Financial Officer (our “CFO”); • Patrick O’Brien, our Chief Operating Officer and General Counsel (our “COO” and “GC”); • Tracie Oliver, our former Chief Commercial Officer (our "CCO"); and • Javier San Martin, our former Chief Medical Officer (our “CMO”). This Compensation Discussion and Analysis describes the material elements of our executive compensation program during fiscal 2024. It also provides an overview of our executive compensation philosophy and objectives and summarizes our executive compensation policies and practices. Finally, it analyzes how and why the Compensation Committee of our Board arrived at the specific compensation decisions for our executive officers, including our NEOs, for fiscal 2024, including the key factors that the Compensation Committee considered in determining their compensation. Our Company We develop medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present